Public Health Considerations Should Guide Patent Examination, Paper Argues
Patent offices should align their work in support of national health and medicines policies when carrying out the examination of patents, a new South Centre paper argues.
Intellectual Property Watch
Original news and analysis on international IP policy
Category WHO
Expert: As A UN Agency, WIPO Has Role To Play On Neglected Diseases
According to a prominent researcher in the field of neglected tropical diseases, the World Intellectual Property Organization has a prominent role to play in addressing the lack of research and development for neglected diseases.
Panellists: Price Is Main Barrier To Medicines Access In Rich And Poor Countries
A joint symposium of the World Health Organization, World Trade Organization and World Intellectual Property Organization this week included several panels on how trade, public health and intellectual property could positively interact to increase access to medicines.
Academic Tells WTO, WIPO, WHO To Stop Using The Term “Developing Countries”
A lively keynote address urging international organisations to adopt a fact-based view of the world and new ways of segmenting countries in an increasingly convergent world, set the scene for the annual trilateral symposium on public health, intellectual property and trade taking place at the World Trade Organization today.
WIPO, WTO, WHO Heads Underline Need For Better Access To Medicines
Trade, health, and intellectual property came together today as the heads of three specialised international organisations held an annual symposium to stimulate discussions on how the three can best help public health, and notably access to medicines in developing countries.
Special Report: WHO Advisory Group On Flu Preparedness Hears Comments, Addresses New Genetics Issue
World Health Organization members and stakeholders were invited to provide comments this month on the organisation’s framework to spur preparedness for future influenza pandemics and ensure treatments will reach developing countries. The framework is expected to undergo a review in 2016. The advisory group to the initiative also went through issues such as contributions by manufacturers, and how to deal with genetic sequence data.
Chatham House Report On Antibiotics Gives Evidence For Drug R&D Delinkage
A new report from Chatham House presenting suggestions for novel business models for antibiotics calls for models in which the return on investment in research and development is not dependent on the volume of sales, also known as delinkage.
UN SDGs Need U-Turn On Governance For Health
The 2030 Agenda for Sustainable Development, to be adopted this week at UN Headquarters, could fall short of its health targets unless the governments embark on “U-turn” changes to rectify the dysfunctions in global governance that undermine health, writes Daniele Dionisio.
Neglected Diseases R&D Initiative To Expand Portfolio To Hepatitis C, New Antibiotics
The Drugs for Neglected Diseases initiative (DNDi) is moving into new disease areas and has moved away from one, it announced this week.
Universal Health Coverage, Millennium Development Goals And Post-2015: The Improvable Way Forward
The negotiating process to achieve post-2015 development goals has clarified the agenda that governments ought to follow until 2030. Unfortunately, due to vague terms and the lack of unequivocal definitions, a number of relevant issues still lie in uncertainty, writes Pietro Dionisio